Semler Scientific (SMLR) versus The Competition Financial Analysis

Semler Scientific (OTCMKTS: SMLR) is one of 47 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare Semler Scientific to similar businesses based on the strength of its risk, dividends, profitability, valuation, earnings, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

0.8% of Semler Scientific shares are held by institutional investors. Comparatively, 42.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 13.9% of Semler Scientific shares are held by insiders. Comparatively, 15.4% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Semler Scientific and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Semler Scientific 0 0 2 0 3.00
Semler Scientific Competitors 187 547 1118 46 2.54

Semler Scientific currently has a consensus price target of $44.00, suggesting a potential upside of 39.68%. As a group, “Electromedical equipment” companies have a potential upside of 14.78%. Given Semler Scientific’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Semler Scientific is more favorable than its peers.

Profitability

This table compares Semler Scientific and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Semler Scientific 19.66% -982.53% 74.53%
Semler Scientific Competitors -129.98% -102.32% -25.44%

Volatility & Risk

Semler Scientific has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Semler Scientific’s peers have a beta of 1.57, suggesting that their average stock price is 57% more volatile than the S&P 500.

Earnings & Valuation

This table compares Semler Scientific and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Semler Scientific $12.45 million -$1.51 million -112.50
Semler Scientific Competitors $1.25 billion $101.33 million -18.50

Semler Scientific’s peers have higher revenue and earnings than Semler Scientific. Semler Scientific is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Semler Scientific peers beat Semler Scientific on 8 of the 13 factors compared.

About Semler Scientific

Semler Scientific, Inc. develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as organizations, including healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry; and other healthcare organizations, such as risk assessment groups and other home healthcare providers. It offers its products through salespersons and distributors. Semler Scientific, Inc. was founded in 2007 and is headquartered in San Jose, California.

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply